Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing to Advance Next-Generation Precision Editing Therapeutics

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2YwLqIJ
via IFTTT